Part:BBa_K5083002

Bimagrumab

Bimagrumab is a humanized monoclonal antibody that binds to type II receptor on muscle cell surfaces. It is primarily used to treat muscle wasting diseases and has been evaluated in multiple clinical trials. Bimagrumab targets ActRIIA and ActRIIB, which play crucial roles in mediating myostatin and activin signaling pathways, thereby preventing muscle wasting and increasing skeletal muscle density. We demonstrated through Western blotting that Bimagrumab can be expressed in Escherichia coli BL21.

Description

Considering that obesity often leads to muscle loss during weight loss, which in turn can cause a range of health problems, we have chosen to express Bimagrumab in probiotics. This approach aims to help patients prevent muscle loss while losing weight. Bimagrumab, derived from Homo sapiens, can block the ActRIIA/ActRIIB signaling pathways, thereby preventing muscle wasting.

Usage and Biology

We utilized the ribosome binding site from the iGEM part library (BBa_B0034) followed by the sequence fragment of Bimagrumab. To express Bimagrumab, we used a constitutive promoter (BBa_J23100) and a strong terminator (BBa_B0015). Finally, we employed the pET23b vector as the plasmid and transformed it into Escherichia coli BL21.

Fig 1.genetic circuit diagram

Potential application directions

Fig 2.Western blotting validation of Bimagrumab expression.

As shown in the figure, Western blotting results indicate that Bimagrumab can be effectively expressed in the engineered Escherichia coli BL21. Furthermore, with the assistance of the PelB signal peptide for secretion, Bimagrumab is successfully secreted into the extracellular space.

Sequence and Features

Assembly Compatibility:

• 10
  COMPATIBLE WITH RFC[10]
• 12
  COMPATIBLE WITH RFC[12]
• 21
  COMPATIBLE WITH RFC[21]
• 23
  COMPATIBLE WITH RFC[23]
• 25
  COMPATIBLE WITH RFC[25]
• 1000
  COMPATIBLE WITH RFC[1000]